Trial Profile
Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG interleukin-29 Administered in Combination With Ribavirin to Treatment-Naive Subjects With Chronic Hepatitis C Virus Infection
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Peginterferon lambda-1a (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms EMERGE
- Sponsors ZymoGenetics
- 25 Jul 2022 This trial has been completed in France (End Date: 20 Jan 2012), according to European Clinical Trials Database record.
- 13 Nov 2012 Primary endpoint 'Early-virological-response-rate' has been met.
- 12 Nov 2012 Results from genotype 1 and 4 patients were presented at the American Association for the Study of Liver Diseases (AASLD) congress, according to a Bristol-Myers Squibb media release.